We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00596115
Expanded Access Status : Temporarily not available
First Posted : January 16, 2008
Last Update Posted : July 25, 2012
University of Pittsburgh
University of Nebraska
Information provided by (Responsible Party):
Bennett, James P., Jr., M.D., Ph.D.

Brief Summary:
R(+) pramipexole dihydrochloride monohydrate [R(+)PPX], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.

Condition or disease Intervention/treatment
Amyotrophic Lateral Sclerosis Drug: R(+) pramipexole dihydrochloride monohydrate

Layout table for study information
Study Type : Expanded Access
Official Title: Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day

Intervention Details:
  • Drug: R(+) pramipexole dihydrochloride monohydrate
    20 mg tid per day orally

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Definite diagnosis of ALS

Exclusion Criteria:

  • No prior participation in R(+)PPX clinical studies

No Contacts or Locations Provided
Layout table for additonal information
Responsible Party: Bennett, James P., Jr., M.D., Ph.D.
ClinicalTrials.gov Identifier: NCT00596115    
Other Study ID Numbers: 12316
First Posted: January 16, 2008    Key Record Dates
Last Update Posted: July 25, 2012
Last Verified: July 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents